Nothing Special   »   [go: up one dir, main page]

WO2000060077A3 - Compounds for therapy and diagnosis of lung cancer and methods for their use - Google Patents

Compounds for therapy and diagnosis of lung cancer and methods for their use Download PDF

Info

Publication number
WO2000060077A3
WO2000060077A3 PCT/US2000/008560 US0008560W WO0060077A3 WO 2000060077 A3 WO2000060077 A3 WO 2000060077A3 US 0008560 W US0008560 W US 0008560W WO 0060077 A3 WO0060077 A3 WO 0060077A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
diagnosis
therapy
protein
methods
Prior art date
Application number
PCT/US2000/008560
Other languages
French (fr)
Other versions
WO2000060077A2 (en
Inventor
Steven G Reed
Michael J Lodes
Raodoh Mohamath
Heather Secrist
Original Assignee
Corixa Corp
Steven G Reed
Michael J Lodes
Raodoh Mohamath
Heather Secrist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/370,838 external-priority patent/US6444425B1/en
Application filed by Corixa Corp, Steven G Reed, Michael J Lodes, Raodoh Mohamath, Heather Secrist filed Critical Corixa Corp
Priority to AU41851/00A priority Critical patent/AU4185100A/en
Priority to JP2000609568A priority patent/JP2002540790A/en
Priority to EP00921551A priority patent/EP1187915A2/en
Publication of WO2000060077A2 publication Critical patent/WO2000060077A2/en
Publication of WO2000060077A3 publication Critical patent/WO2000060077A3/en
Priority to HK02106838.1A priority patent/HK1045332A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.
PCT/US2000/008560 1999-04-02 2000-03-30 Compounds for therapy and diagnosis of lung cancer and methods for their use WO2000060077A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU41851/00A AU4185100A (en) 1999-04-02 2000-03-30 Compounds for therapy and diagnosis of lung cancer and methods for their use
JP2000609568A JP2002540790A (en) 1999-04-02 2000-03-30 Compounds for the treatment and diagnosis of lung cancer and methods for their use
EP00921551A EP1187915A2 (en) 1999-04-02 2000-03-30 Compounds for therapy and diagnosis of lung cancer and methods for their use
HK02106838.1A HK1045332A1 (en) 1999-04-02 2002-09-19 Compounds for therapy and diagnosis of lung cancer and methods for their use

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US28532399A 1999-04-02 1999-04-02
US09/285,323 1999-04-02
US09/370,838 1999-08-09
US09/370,838 US6444425B1 (en) 1999-04-02 1999-08-09 Compounds for therapy and diagnosis of lung cancer and methods for their use
US47623599A 1999-12-30 1999-12-30
US09/476,235 1999-12-30
US51880900A 2000-03-03 2000-03-03
US09/518,809 2000-03-03

Publications (2)

Publication Number Publication Date
WO2000060077A2 WO2000060077A2 (en) 2000-10-12
WO2000060077A3 true WO2000060077A3 (en) 2002-01-17

Family

ID=27501392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008560 WO2000060077A2 (en) 1999-04-02 2000-03-30 Compounds for therapy and diagnosis of lung cancer and methods for their use

Country Status (5)

Country Link
EP (1) EP1187915A2 (en)
JP (1) JP2002540790A (en)
AU (1) AU4185100A (en)
HK (1) HK1045332A1 (en)
WO (1) WO2000060077A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
GB9924060D0 (en) * 1999-10-11 1999-12-15 Chiron Spa VIP54 protein
CA2404233A1 (en) * 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2001280198A1 (en) * 2000-08-28 2002-03-13 Teijin Limited Airway-specific trypsin-like enzymes and method of using the same
CA2489623A1 (en) 2001-06-21 2003-01-03 Isis Innovation Limited Atopy
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7906620B2 (en) * 2002-08-16 2011-03-15 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
AU2007216892B2 (en) * 2002-08-16 2011-02-10 Agensys, Inc. Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
JP5648261B2 (en) * 2006-12-20 2015-01-07 東レ株式会社 Cancer detection method
EP2733492B1 (en) * 2008-08-05 2016-02-24 Toray Industries, Inc. Cancer detection method
BRPI0911926A2 (en) 2008-08-05 2020-08-18 Toray Industries, Inc pharmaceutical compositions, antibodies and uses of an antibody or a fragment thereof.
WO2011096533A1 (en) * 2010-02-04 2011-08-11 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of cancer
RU2567657C2 (en) 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Pharmaceutical composition for treating and/or preventing cancer
CA2788718C (en) 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
PT2532365T (en) * 2010-02-04 2016-07-28 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer
US8911740B2 (en) 2010-02-04 2014-12-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PT2532367T (en) 2010-02-04 2018-11-09 Toray Industries Pharmaceutical agent for treatment and/or prevention of cancer
RU2641260C2 (en) 2011-08-04 2018-01-16 Торэй Индастриз, Инк. Pharmaceutical composition for cancer treatment and prevention
PL2740489T3 (en) 2011-08-04 2017-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
MX348581B (en) 2011-08-04 2017-06-20 Toray Industries Cancer treatment and/or prevention drug composition.
CN103764825B (en) 2011-08-04 2015-09-02 东丽株式会社 Cancer treat and/or prevent pharmaceutical composition
TR201802089T4 (en) 2011-08-04 2018-03-21 Toray Industries Drug composition for the treatment and / or prevention of cancer.
PT2740794T (en) 2011-08-04 2018-06-14 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer
BR112014021103A2 (en) 2012-02-21 2019-10-15 Toray Industries, Inc ANTIBODY, PHARMACEUTICAL COMPOSITION, COMBINATION DRUG, DNA, METHOD OF TREATMENT AND USE OF ANTIBODY
JP6187256B2 (en) 2012-02-21 2017-08-30 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
RU2639522C2 (en) 2012-02-21 2017-12-21 Торэй Индастриз, Инк. Pharmaceutical composition for cancer treatment and/or prevention
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
EP2832365B1 (en) 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
PL2876446T3 (en) 2012-07-19 2019-06-28 Toray Industries, Inc. Method for detecting cancer
US9862774B2 (en) 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002552A1 (en) * 1994-07-19 1996-02-01 Cytoclonal Pharmaceutics, Inc. Lung cancer marker
WO1999038973A2 (en) * 1998-01-28 1999-08-05 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002552A1 (en) * 1994-07-19 1996-02-01 Cytoclonal Pharmaceutics, Inc. Lung cancer marker
WO1999038973A2 (en) * 1998-01-28 1999-08-05 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN S-L ET AL: "Isolation and characterizaton of a novel gene expressed in multiple cancers", ONCOGENE,GB,BASINGSTOKE, HANTS, vol. 12, no. 4, 15 February 1996 (1996-02-15), pages 741 - 751-751, XP002106655, ISSN: 0950-9232 *
GÜRE ET AL: "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 58, no. 58, 1 March 1998 (1998-03-01), pages 1034 - 1041-41, XP002103188, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
AU4185100A (en) 2000-10-23
JP2002540790A (en) 2002-12-03
WO2000060077A2 (en) 2000-10-12
HK1045332A1 (en) 2002-11-22
EP1187915A2 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001075171A3 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001051513A3 (en) Ovarian tumor-associated sequences
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609568

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000921551

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000921551

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000921551

Country of ref document: EP